WO2011115323A1 - 디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 - Google Patents
디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 Download PDFInfo
- Publication number
- WO2011115323A1 WO2011115323A1 PCT/KR2010/002277 KR2010002277W WO2011115323A1 WO 2011115323 A1 WO2011115323 A1 WO 2011115323A1 KR 2010002277 W KR2010002277 W KR 2010002277W WO 2011115323 A1 WO2011115323 A1 WO 2011115323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- dlk1
- fusion protein
- domain
- inhibiting
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Definitions
- the present invention relates to a composition for inhibiting cancer metastasis, which contains DLK1-Fc fusion protein having cancer metastasis suppression ability.
- Cancer is a major disease that threatens human life. In South Korea, cancer is the number one cause of death in the past few years, and cancer is the second leading cause of death in the United States, after cardiovascular disease. Although much research has been carried out and is still being carried out, cancer is still the greatest catastrophe of civilization and a fatal disease with millions of lives and astronomical economic losses every year.
- Cancer is a genetic disease caused by mutations in genes such as oncogenes and tumor suppressor genes, and is a disease caused at the cellular level. Surgical surgery, drug therapy, radiation therapy and immunotherapy are currently used for the treatment of cancer, but suppression and recurrence of malignant tumors are still unresolved.
- cancer metastasis One of the most important biological properties of cancer is that it can cause metastasis, which is considered the biggest obstacle to treating cancer. In fact, about 60% of all solid tumor patients already have cancers that have been clinically metastasized at the time of primary tumor diagnosis, and it is well known that the major cause of death in most cancer patients is cancer metastasis.
- Neovascularization which is accompanied by infiltration of local tissues of cancer during metastasis, involves tumor angiogenesis factors, and blood vessels newly formed by tumors are easily invaded by cancer cells. do.
- cancer invasion and metastasis processes involve numerous cancer cell surface receptors such as laminin receptors required for adhesion to tissue matrix and basement membrane, type IV collagenase, plasminogen activator and cathepsin Expression of numerous enzymes, growth factors, autocrine motility factors and cancer genes required to dissolve normal tissue epilepsy such as D is required.
- DLK1 delta-like 1 homolog
- DLK1 belongs to the notch / delta / serrate family is a transmembrane glycoprotein encoded by the dlk1 gene located on chromosome 14q32. It consists of 383 amino acids. The protein is divided into 280 extracellular regions, 24 membrane transmembrane regions, and 56 intracellular regions, and has six epidermal growth factor like repeat domains outside the double membrane, and three It has N-glycosylation and seven O-glycosylation sites.
- DLK1 is a membrane protein, it is well known as a protein that functions as a function of tumor necrosis factor alpha converting enzyme (TACE) that sheds the outer membrane of the cell membrane and functions separately (Yuhui). Wang and Hei Sook Sul, Molecular and cellular biology.26 (14): 5421-5435, 2006).
- DLK1 is found in a variety of forms from 50 to 60 kDa by glycosylation in cell membranes (Smas CM and Sul HS, Cell . 73: 725-34, 1993), and four splicing variants by selective splicing ( splicing variant) (Smas CM et al ., Biochemistry . 33: 9257-65, 1994). Two of these variants have protease cleavage sites and are cleaved by the protease TACE, resulting in two water-soluble forms of 50 kDa and 25 kDa sizes (Yuhui Wang et al., Journal of Nutrition. 136: 2953-2956, 2006) (see FIG. 1).
- DLK1 is mainly expressed at the developmental stage, and the tissue to be expressed is embryonic tissue (Smas CM et al ., Cell. 73: 725-34, 1993; Kaneta M et al., Journal of Immunology. 164: 256-64, 2000 ) And placenta, and are also known as fetal antigen 1 (FA1), especially at high concentrations in maternal serum (Jensen CH et al., European Journal of Biochemistry . 225: 83-92, 1994). Glandular cells of the pancreas (Kaneta M et al., Journal of Immunology .
- DLK1 is absent in most tissues after birth, preadipocyte (Smas CM et al., Cell . 73: 725-34, 1993), pancreatic islet cell (Carlsson C et al) ., Endocrinology 138:. 3940-8, 1997) somatic thymus (thymic stromal cell) (Kaneta M et al, Journal of Immunology 164:..
- DLK1 Downlink kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinasarcoma kinaset al., Endocrinology . 139: 3316-28, 1998).
- Expression of DLK1 is known to be an external monoallelic expression due to the effect of methylation (Schmidt JV et al., Genes and Development . 14: 1997-2002, 2000; Takada S et al., Current Biology 10: 1135-8, 2000; Wylic AA et al, Genome Research . 10: 1711-8, 2000).
- DLK1's functional studies are known as the preadipocyte factor-1, which inhibits adipocyte differentiation, and has been studied the most (Smas CM et al., Cell . 73: 725-34; Villena JA et al., Hormone and Metabolic Research . 34: 664-70, 2002).
- DLK1 inhibits the differentiation of hematopoietic stem cells (Sakajiri S et al., Leukemia . 19: 1404-10, 2005; Li L et al., Oncogene .
- TACE Tumor necrosis factor alpha converting enzyme
- the present inventors construct a recombinant expression vector in which the gene of the Fc domain of the IgG antibody is combined with the water-soluble domain gene of the extracellular region of DLK1 and expresses and purifies DLK1-Fc fusion protein in 293E cells.
- DLK1-Fc fusion protein is effective for inhibiting cancer metastasis.
- the present invention has been completed by confirming that it can be usefully used as a component.
- An object of the present invention is to provide a DLK1-Fc fusion protein, and a composition for inhibiting cancer metastasis containing the same as an active ingredient.
- the present invention provides a water soluble domain of the extracellular region of delta-like 1 homolog (DLK1).
- polynucleotides encoding the water soluble domain of the extracellular region of DLK1, a recombinant vector containing the polynucleotide, and a recombinant cell line in which the recombinant vector has been transformed into a host cell.
- DLK1-Fc fusion proteins conjugated to the water soluble domain of the extracellular region of DLK1, and the human antibody Fc region.
- the present invention also provides a polynucleotide encoding the DLK1-Fc fusion protein, a recombinant vector containing the polynucleotide, and a recombinant cell line in which the recombinant vector is transformed into a host cell.
- the present invention comprises the steps of 1) culturing a recombinant cell line;
- the present invention provides a composition for inhibiting cancer metastasis containing the water-soluble domain or DLK1-Fc fusion protein of the DLK1 extracellular domain prepared as an active ingredient.
- the present invention also provides a method for inhibiting cancer metastasis, comprising administering a pharmaceutically effective amount of the soluble domain of the extracellular region of the prepared DLK1 or DLK1-Fc fusion protein to a subject suffering from metastatic cancer.
- the present invention provides a use of the water-soluble domain or DLK1-Fc fusion protein of the DLK1 extracellular region prepared in the manufacture of a composition for inhibiting cancer metastasis.
- DLK1-Fc fusion protein of the present invention has a higher stability than the non-fusion protein, significantly reduces the migration (migration) in various cancer cell lines and excellent cancer metastasis inhibitory effect at low concentrations, it is effective in the composition for inhibiting cancer metastasis It can be usefully used as a component.
- 1 is a diagram showing the structure of DLK1 protein.
- S signal peptide
- 1-6 epidermal growth factor-like repeat domain
- JM membrane proximity domain
- Tm transmembrane domain
- Cy intracellular domain
- FIG. 2 is a graph showing the expression rate of DLK1 gene in cancer patient tissue.
- 3 is a diagram showing the expression rate of DLK1 gene in cancer cells.
- FIG. 4 is a diagram showing a primer sequence (SEQ ID NO: 5'-CAGGGGGCCGTGGGGGCCGAATGCTTCCCGGCCTGCAA-3 '; SEQ ID NO: 3'5'-TAGCGGCCGACGCGGCCGCCCTCGGTGAGGAGAGGGG-3') used to construct an expression vector for DLK1-Fc fusion protein expression.
- FIG. 5 is a diagram showing the structure of the expression vector pYK602-His-DLK1 vector for the expression of DLK1-Fc fusion protein.
- FIG. 6 is a diagram showing a nucleic acid nucleotide sequence (SEQ ID NO: 1) of the cloned DLK1.
- FIG. 7 is a diagram showing an amino acid sequence (SEQ ID NO: 4) of the cloned DLK1.
- FIG. 8 is a diagram showing the results of inducing the expression of DLK1-Fc fusion protein in 293E cells, recovering the cell culture medium, and confirming the expression of DLK1-Fc fusion protein in the recovered medium.
- FIG. 9 is a diagram showing the results of SDS-polyacrylamide gel to identify the purified DLK1-Fc fusion protein.
- FIG. 10 is a diagram showing the effect of inhibiting the movement of cell culture medium containing DLK1-Fc fusion protein in colorectal cancer cell line SW620.
- FIG. 11 is a diagram showing the effect of inhibiting the migration of cell culture medium containing DLK1-Fc fusion protein in skin cancer melanoma cell line MDA-MB-435.
- FIG. 12 is a diagram showing the migration inhibitory effect of the water-soluble domain of the extracellular domain of DLK1 and the water-soluble DLK1-Fc fusion protein in the skin cancer melanoma cell line MDA-MB-435:
- sDLK1, sDLK1-Fc and Fc use 10 ug / ml.
- FIG. 13 is a graph showing the migration inhibitory effect of the water-soluble domain of the extracellular region of DLK1 and the water-soluble DLK1-Fc fusion protein in the skin cancer melanoma cell line MDA-MB-435:
- sDLK1, sDLK1-Fc and Fc use 10 ug / ml.
- FIG. 14 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in breast cancer cell line Hs578T.
- FIG. 15 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in breast cancer cell line MCF-7.
- Figure 16 shows the migration inhibitory effect of soluble DLK1-Fc fusion protein in uterine cancer cell line HeLa.
- 17 is a diagram showing the effect of inhibiting the migration of water-soluble DLK1-Fc fusion protein in colorectal cancer cell line SW480.
- FIG. 18 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in colorectal cancer cell line HT29.
- Figure 19 shows the migration inhibitory effect of soluble DLK1-Fc fusion protein in kidney cancer cell line 786-O.
- 20 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in kidney cancer cell line UO-31.
- FIG. 21 is a diagram showing the effect of inhibiting the migration of water-soluble DLK1-Fc fusion protein in liver cancer cell line HepG2.
- FIG. 22 is a diagram showing the effect of inhibiting the migration of water-soluble DLK1-Fc fusion protein in liver cancer cell line SNU449.
- Figure 23 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in liver cancer cell line SNU398.
- FIG. 24 is a diagram showing the effect of inhibiting the migration of water-soluble DLK1-Fc fusion protein in lung cancer cell line A549.
- 25 is a diagram showing the effect of inhibiting the migration of water-soluble DLK1-Fc fusion protein in lung cancer cell line NCIH23.
- Figure 26 shows the migration inhibitory effect of soluble DLK1-Fc fusion protein in lung cancer cell line NCIH460.
- Figure 27 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in ovarian cancer cell line MDAH2774.
- FIG. 28 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in ovarian cancer cell line IGROV-1.
- 29 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in pancreatic cancer cell line Aspc-1.
- FIG. 30 is a diagram showing the effect of inhibiting the migration of soluble DLK1-Fc fusion protein in pancreatic cancer cell line HPAC.
- Figure 31 shows the migration inhibitory effect of the soluble DLK1-Fc fusion protein in pancreatic cancer cell line MIA paca-2.
- 32 is a diagram showing the effect of inhibiting the migration of water-soluble DLK1-Fc fusion protein in gastric cancer cell line SNU638.
- FIG. 33 is a diagram showing the effect of inhibiting the migration of water-soluble DLK1-Fc fusion protein in gastric cancer cell line AGS.
- 34 is a diagram showing the number of cells, chemical attractant composition, and incubation time of each cell line used in the experiment for confirming the migration inhibitory effect of the water-soluble DLK1-Fc fusion protein.
- 35 shows the results of drug kinetics experiments of water-soluble DLK1-Fc fusion protein.
- the present invention relates to a polynucleotide encoding the water soluble domain of the extracellular region of DLK1 (delta-like 1 homolog), a polynucleotide encoding the water soluble domain of the extracellular region of DLK1, a recombinant vector containing the polynucleotide, and a recombinant vector to the host cell. Provide a transformed recombinant cell line.
- the water soluble domain of the extracellular region of DLK1 preferably has an amino acid sequence as set forth in SEQ ID NO: 4, but is not limited thereto.
- the polynucleotide encoding the water soluble domain preferably has a gene sequence set forth in SEQ ID NO: 1, but is not limited thereto.
- the present invention also provides a DLK1-Fc fusion protein in which the water-soluble domain of the extracellular region of the DLK1 and the human IgG Fc region are conjugated.
- DLK1-Fc fusion protein refers to a recombinant molecule comprising fragments derived from the constant domain of the heavy chain of an antibody.
- Fc fusion proteins may comprise all or a portion of the Fc domains, ie CH2 and CH3 constant domains, of antibodies from any of five Ig classes (eg, IgA, IgD, IgE, IgG and IgM).
- the DLK1-Fc fusion protein may be made in a form comprising all or part of the constant domain region of the heavy chain of the antibody at the carboxy- and amino-terminus of the extracellular soluble domain of DLK1. .
- the Fc fusion protein may also include a form having a constant domain region of the heavy chain of two or more antibodies, wherein the two heavy chains Fc may be linked by disulfide bonds or other covalent bonds.
- the DLK1 portion of the DLK1-Fc fusion protein may also include a form having regions of two or more extracellular soluble domains of DLK1.
- the present invention also provides a polynucleotide encoding the DLK1-Fc fusion protein, a recombinant vector containing the polynucleotide, and a recombinant cell line in which the recombinant vector is transformed into a host cell.
- the expression vector including the gene is a pYK602-His vector, but is not limited thereto.
- a vector including a mammalian expression promoter and an Fc domain may be used.
- the mammalian cells are 293E cells, but are not limited thereto. Any mammalian cell line capable of operating a promoter may be used.
- DLK1 could be assumed to play a role as a tumor suppressor gene in addition to the characteristics of the oncogene, in particular Tumor necrosis factor alpha converting enzyme TACE) allows the study to use only water-soluble domains that shedding the outer membrane of the cell membrane from the cell membrane to autocrine effects as well as to other paracrine effects. Proceeded.
- Water-soluble Fc fusion proteins are widely used in in vitro experiments and in vivo experiments, and have many advantages, such as higher stability than non-fusion proteins, especially in animal experiments (Meg L et. al., Methods in Molecular Biology 378: 33-52, 2007).
- Representative water-soluble Fc fusion human antibody preparations include Amtan's therapeutic agent for arthritis, Etanercept, which is made by fusion of Fc of human IgG1 to the water-soluble domain of TNF receptor 2 (US Patent number: 5447851).
- a diene in order to clone DLK1 into the pYK602-His vector, a diene is described in the diene using primers described as SEQ ID NOs: 2 (5'-CAGGGGGCCGTGGGGGCCGAATGCTTCCCGGCCTGCAA-3 ') and 3 (5'-TAGCGGCCGACGCGGCCGCCCTCGGTGAGGAGAGGGG-3').
- SEQ ID NOs: 2 5'-CAGGGGGCCGTGGGGGCCGAATGCTTCCCGGCCTGCAA-3 '
- 3 5'-TAGCGGCCGACGCGGCCGCCCTCGGTGAGGAGAGGGG-3'
- Polymerase chain reaction was performed using a library mix (mixture of kidney, placenta, pancreas and liver) to amplify only the water-soluble domain of the extracellular domain of DLK1 protein.
- the resulting polymerase chain reaction resulted in restriction enzyme reaction with SfiI.
- pYK602-His-DLK1 DNA was transformed into 293E cells, and the medium was recovered to confirm the expression of DLK1-Fc fusion protein by Western blot method (see FIG. 8).
- the expression medium was purified using a Protein A column, and the purified DLK1-Fc protein was neutralized to pH, followed by dialysis using PBS (Potassium phosphate saline) buffer, followed by BCA analysis. Through quantification and SDS-PAGE was performed to confirm the purification and quantification (see Fig. 9).
- the purified DLK1-Fc fusion protein was then removed with bacterial endotoxin using an EndoTrap Red column, thereby preparing DLK1-Fc fusion protein.
- the present invention provides a composition for inhibiting cancer metastasis comprising the water-soluble domain of the DLK1 extracellular region, or DLK1-Fc fusion protein prepared as an active ingredient.
- the cancer is skin cancer, liver cancer, stomach cancer, breast cancer, colon cancer, bone cancer, pancreatic cancer, head or neck cancer, uterine cancer, colon cancer, lung cancer, ovarian cancer, rectal cancer, esophageal cancer, small intestine cancer, anal muscle cancer, colon cancer, fallopian tube carcinoma, endometrium Carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, prostate cancer, bladder cancer, kidney cancer, ureter cancer, renal cell carcinoma, renal pelvic carcinoma and central nervous system tumors It is more preferably one selected from the group consisting of skin cancer, breast cancer, uterine cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer, but is not limited thereto.
- cancer cells using the method of reference (Chen HC, Methods in molecular biology. 294: 15-22, 2005) to determine the effect of the prepared DLK1-Fc fusion protein on cancer cell lines
- the migration assay was performed, and the effects of the purified DLK1-Fc fusion protein on metastasis of various cancer cell lines were examined.
- skin cancer see FIG. 11
- breast cancer see FIGS. 14 and 15
- uterine cancer 16
- colorectal cancer see FIGS. 17 and 18
- kidney cancer see FIGS. 19 and 20
- liver cancer see FIGS. 21-23
- lung cancer see FIGS. 24-26
- ovarian cancer FIGS. 27 and 28
- the water-soluble domain of the extracellular region of the prepared DLK1, or DLK1-Fc fusion protein can be usefully used as a composition for inhibiting cancer metastasis containing the same as an active ingredient.
- composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions.
- it may be prepared further comprising one or more pharmaceutically acceptable carriers.
- the composition of the present invention comprises 0.0001 to 10% by weight of the protein, preferably 0.001 to 1% by weight, based on the total weight of the composition.
- Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, as necessary, including antioxidants, buffers, Other conventional additives such as bacteriostatic agents can be added.
- diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate into main dosage forms, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
- the composition for inhibiting cancer metastasis of the present invention may be parenterally administered (for example, intravenously, intramuscularly, intraperitoneally, subcutaneously or topically) or orally according to a desired method, and the dosage may be administered by the weight of the patient,
- the range varies depending on age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease.
- the dose of the protein according to the present invention is 0.738 ug to 7.38 g assuming 60 kg of an adult male (based on US FDA), preferably 7.38 ug to 0.738 g (12.3 mpk).
- the method of administration can be determined according to patient needs.
- the present invention also provides a method for inhibiting cancer metastasis, comprising administering a pharmaceutically effective amount of the soluble domain of the extracellular region of the prepared DLK1 or DLK1-Fc fusion protein to a subject suffering from metastatic cancer.
- the water soluble domain of the extracellular region of DLK1 preferably has an amino acid sequence as set forth in SEQ ID NO: 4, but is not limited thereto.
- DLK1-Fc fusion protein refers to a recombinant molecule comprising fragments derived from the constant domain of the heavy chain of an antibody.
- Fc fusion proteins may comprise all or a portion of the Fc domains, ie CH2 and CH3 constant domains, of antibodies from any of five Ig classes (eg, IgA, IgD, IgE, IgG and IgM).
- the DLK1-Fc fusion protein may be made in a form comprising all or part of the constant domain region of the heavy chain of the antibody at the carboxy- and amino-terminus of the extracellular soluble domain of DLK1. .
- the Fc fusion protein may also include a form having a constant domain region of the heavy chain of two or more antibodies, wherein the two heavy chains Fc may be linked by disulfide bonds or other covalent bonds.
- the DLK1 portion of the DLK1-Fc fusion protein may also include a form having regions of two or more extracellular soluble domains of DLK1.
- the cancer is skin cancer, liver cancer, stomach cancer, breast cancer, colon cancer, bone cancer, pancreatic cancer, head or neck cancer, uterine cancer, colon cancer, lung cancer, ovarian cancer, rectal cancer, esophageal cancer, small intestine cancer, anal muscle cancer, colon cancer, fallopian tube carcinoma, endometrium Carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, prostate cancer, bladder cancer, kidney cancer, ureter cancer, renal cell carcinoma, renal pelvic carcinoma and central nervous system tumors It is more preferably one selected from the group consisting of skin cancer, breast cancer, uterine cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer, but is not limited thereto.
- the method of inhibiting cancer metastasis of the present invention may be parenterally administered (eg, applied intravenously, intramuscularly, intraperitoneally, subcutaneously or topically) or orally as desired, and the dosage may be based on the weight, age, The range varies depending on sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of disease.
- the dose of the protein according to the present invention is 0.738 ug to 7.38 g assuming 60 kg of an adult male (based on US FDA), preferably 7.38 ug to 0.738 g (12.3 mpk).
- the method of administration can be determined according to patient needs.
- the present invention constructs a recombinant expression vector which combines the Fc domain gene of IgG antibody with the water soluble domain gene of the extracellular domain of DLK1, expresses and purifies DLK1-Fc fusion protein in 293E cells, Since the efficiency as a drug of the actual cancer metastasis inhibition concept through the reduction of the migration of cancer cells by the -Fc fusion protein and the calculation of drug kinetics parameters was confirmed, the water-soluble domain or DLK1-Fc of the extracellular domain of DLK1 of the present invention.
- the fusion protein can be usefully used in a method of inhibiting cancer metastasis.
- the present invention provides a use of the water-soluble domain or DLK1-Fc fusion protein of the DLK1 extracellular region prepared in the manufacture of a composition for inhibiting cancer metastasis.
- the water soluble domain of the extracellular region of DLK1 preferably has an amino acid sequence as set forth in SEQ ID NO: 4, but is not limited thereto.
- DLK1-Fc fusion protein refers to a recombinant molecule comprising fragments derived from the constant domain of the heavy chain of an antibody.
- Fc fusion proteins may comprise all or a portion of the Fc domains, ie CH2 and CH3 constant domains, of antibodies from any of five Ig classes (eg, IgA, IgD, IgE, IgG and IgM).
- the DLK1-Fc fusion protein may be made in a form comprising all or part of the constant domain region of the heavy chain of the antibody at the carboxy- and amino-terminus of the extracellular soluble domain of DLK1. .
- the Fc fusion protein may also include a form having a constant domain region of the heavy chain of two or more antibodies, wherein the two heavy chains Fc may be linked by disulfide bonds or other covalent bonds.
- the DLK1 portion of the DLK1-Fc fusion protein may also include a form having regions of two or more extracellular soluble domains of DLK1.
- the cancer is skin cancer, liver cancer, stomach cancer, breast cancer, colon cancer, bone cancer, pancreatic cancer, head or neck cancer, uterine cancer, colon cancer, lung cancer, ovarian cancer, rectal cancer, esophageal cancer, small intestine cancer, anal muscle cancer, colon cancer, fallopian tube carcinoma, endometrium Carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, prostate cancer, bladder cancer, kidney cancer, ureter cancer, renal cell carcinoma, renal pelvic carcinoma and central nervous system tumors It is more preferably one selected from the group consisting of skin cancer, breast cancer, uterine cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer, but is not limited thereto.
- the present invention constructs a recombinant expression vector which combines the Fc domain gene of IgG antibody with the water soluble domain gene of the extracellular domain of DLK1, expresses and purifies DLK1-Fc fusion protein in 293E cells, Since the efficiency as a drug of the actual cancer metastasis inhibition concept through the reduction of the migration of cancer cells by the -Fc fusion protein and the calculation of drug kinetics parameters was confirmed, the water-soluble domain or DLK1-Fc of the extracellular domain of DLK1 of the present invention.
- the fusion protein can be usefully used for the production of a composition for inhibiting cancer metastasis.
- composition for inhibiting cancer metastasis of the present invention may further contain one or more active ingredients exhibiting the same or similar functions.
- it may be prepared further comprising one or more pharmaceutically acceptable carriers.
- the composition of the present invention comprises 0.0001 to 10% by weight of the protein, preferably 0.001 to 1% by weight, based on the total weight of the composition.
- Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, as necessary, including antioxidants, buffers, Other conventional additives such as bacteriostatic agents can be added.
- diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate into main dosage forms, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
- the composition for inhibiting cancer metastasis of the present invention may be parenterally administered (for example, intravenously, intramuscularly, intraperitoneally, subcutaneously or topically) or orally according to a desired method, and the dosage may be administered by the weight of the patient,
- the range varies depending on age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease.
- the dose of the protein according to the present invention is 0.738 ug to 7.38 g assuming 60 kg of an adult male (based on US FDA), preferably 7.38 ug to 0.738 g (12.3 mpk).
- the method of administration can be determined according to patient needs.
- a pair of primers having base sequences described as SEQ ID NOs: 2 (5'-CAGGGGGCCGTGGGGGCCGAATGCTTCCCGGCCTGCAA-3 ') and 3 (5'-TAGCGGCCGACGCGGCCGCCCTCGGTGAGGAGAGGGG-3'), respectively
- the polymerase chain reaction was carried out. Specifically, the reaction combination was 100 ng of the DNA library mix (kidney, placenta, pancreas, liver mixed) used as a template, 10 pmol each of the pfu 2.5 unit primer was added and the reaction was carried out with a total of 50 ul.
- the reaction was terminated with 1 cycle of 94 degrees 2 minutes, 1 cycle 94 degrees 30 seconds, 55 degrees 30 seconds, 72 degrees 1 minute, 30 cycles, 72 degrees 10 minutes.
- the result of the polymerase chain reaction includes the SfiI restriction enzyme site, and after performing the restriction enzyme reaction with SfiI, the pYK602-HIS vector was added to prepare a pYK602-His-DLK1 recombinant vector (FIG. 5).
- the cloned DLK1 is a water-soluble domain outside the cell membrane that corresponds to the 25th to 302th amino acids among 383 amino acids, and removes the signal peptide and the cytoplasmic domain under the transmembrane region.
- the nucleic acid base sequence and amino acid sequence of the cloned DLK1 are shown in Figure 6 (SEQ ID NO: 1) and 7 (SEQ ID NO: 4).
- 293E cells were used to express the DLK1-Fc cloned in ⁇ Example 1>.
- Specific expression method is as follows. 10 ug of DNA and 20 ug of PEI (# 23966, Polysciences, USA) were mixed at a cell level of about 70% on a 100 mm plate, and then reacted at room temperature for 20 minutes to prepare a mixture and then treated the cells. After 16 to 10 hours, the medium was changed to serum-free DMEM medium, and the medium was collected every other day and then replaced with fresh medium. The recovered medium was confirmed by Western blot method (Fig. 8). Expression medium was confirmed by removing the cells that may remain by centrifugation, and filtered using a 0.22um filter (# PR02890 Millipore, USA).
- Purification was then performed using a Protein A column. This was filled with 500 ul of protein A beads (# 17-1279-03 GE, Sweden) in a 10 ml column, washed with PBS, and then flowed in a medium expressing DLK1-Fc. This process was done using a Perry-start pump, set at a flow rate of 0.5 ml per minute. After passing through the column, the medium was washed with PBS, and the DLK1-Fc protein was purified with 0.1 M glycine-HCl (# G7126, Sigma, USA). The recovered protein was neutralized with 1M Tris pH 9.0 (# T-1503, Sigma, USA) and dialyzed with PBS. Purified protein was quantitated by BCA analysis, and SDS-PAGE was performed to determine whether it was purified (FIG. 9), thereby obtaining a purified DLK1-Fc fusion protein.
- Chromo-LAL (cat # C0031, CAPE COD) was used to measure bacterial endotoxin levels of DLK1-Fc prepared and purified in Example 2.
- CSE control standard endotoxin; cat # E0005, CAPE COD
- CSE control standard endotoxin; cat # E0005, CAPE COD
- LRW LAL reagent water; cat # WP1001, CAPE COD
- 100 ul of LAL and 100 ul of standard 100ul + LAL at a concentration of 0.125EU / ml as a positive control.
- Standard curves are plotted with Log EU / mL on the X-axis and Log Onset time on the Y-axis.
- the endotoxin values of the samples are automatically calculated by the software and displayed in EU / ml. Reliability was measured when the R 2 value of the standard curve was above 0.98.
- LAL test results for the DLK1-Fc protein were determined to contain 150.24 EU / ml of endotoxin.
- the EndoTrap Red (cat # 83-009U, Lonza) column was then used to remove the endotoxin of the sample. The column is washed twice with 3 ml of regeneration buffer and then twice with the same amount of stabilization buffer.
- Example 2 In order to determine the effect of the DLK1-Fc protein prepared and purified in Example 2 on cancer cell lines, the method of Reference (Chen HC, Methods in molecular biology. 294: 15-22, 2005) was used. Cancer cell line migration assay was performed.
- cancer cell lines [skin cancer cell lines (MDA-MB-435; ATCC HTB-129), breast cancer cell lines (Hs578T; ECACC 86082104 and MCF-7; ATCC HTB-22), uterine cancer cell lines (HeLa; ATCC CCL-2), Colorectal cancer cell lines (SW480; ATCC CCL-228, SW620; ATCC CCL-227 and HT29; ATCC HTB-38), Kidney cancer cell lines (786-O; ATCC CRL-1932 and UO-31; DTP), Liver cancer cell lines (HepG2 ; ATCC HB-8065, SNU398; KCLB 00398 and SNU449; KCLB 00449), lung cancer cell lines (A549; ATCC CCL-185, NCIH23; KCLB 90023 and NCIH460; KCLB 30177), ovarian cancer cell lines (MDAH2774; ATCC CRL-10303 and IGROV -1; DTP), pancreatic cancer cell lines (
- Cells, serum-free medium and each protein to be treated were combined to make 100 ul and incubated at 37 ° C. for 1 hour.
- 1 ml of a chemo-attractant is placed in a 24-well plate, a transwell (Corning # 3422) with a 8.0 um pore is placed thereon and pre-incubated for 1 hour in cells, 100 ul of the protein mixture was added and then incubated for 24 hours to 48 hours in a 37 °C carbon dioxide incubator.
- the number of cells used in each cell line, the composition of chemical attractants, and the incubation time are shown in FIG. 21.
- the medium of the transwell was removed, and then fixed for 15 minutes in 100% methanol, and then washed twice with distilled water, followed by reaction for 5 minutes in a crystal violet solution. After the reaction was washed three times in distilled water, cells that did not pass through the transwell using a cotton swab to remove completely using a cotton swab. After the transwells were completely dried, observations and photographs were taken at a magnification of 100 times to observe the cells that had passed through the transwells. For quantitative analysis, after photographing, the absorbance was analyzed by immersing in a 10% acetic acid in transwell and extracting it at 560nm wavelength.
- cell culture solution containing water-soluble DLK1-Fc fusion protein was treated to colon cancer cell line SW620 and skin cancer melanoma cell line MDA-MB-435. It was confirmed that significantly inhibit the migration (migration) of the cancer cell line compared to the protein and untreated group (Figs. 10 and 11). In addition, in order to determine that migration is not the effect of Fc bound to DLK1, only the water-soluble portion of DLK1 was expressed and purified and compared. As a result, a significant decrease in migration of cancer cell lines, such as water-soluble DLK1-Fc fusion protein, was confirmed. 13).
- the pharmacokinetic experiment was performed to determine whether the DLK1-Fc fusion protein prepared and purified in ⁇ Example 2> is suitable for use as an actual anti-transduction inhibitor.
- Balb / c females were inoculated once at 5 mg / kg by intraperitoneal injection at 6 weeks of age (Orient Bio) and then every 0, 0.5, 2, 4, 6, 24, 30, 48 hours in ophtalmic venus plexus. After collecting blood, serum was separated and used for the experiment.
- the enzyme immunoassay was used to measure the concentration of DLK1-Fc in the blood using the sampled serum. Specifically, enzyme immunoassay plates (# 439454, NUNC) were coated with DLK1 antibody (# MAB1144, R & D) at a concentration of 1 ug / ml at 4 ° C. After blocking for 1 hour with 4% Scheme Milk / PBS (potassium phosphate saline) buffer, the plates were washed with PBST (potassium phosphate saline, 0.05% Tween 20) buffer. For construction of standard curves, purified DLK1-Fc was diluted 2-fold starting at 100 nM concentration and hIgG (human IgG) was used as a negative control.
- PBST potential phosphate saline
- Serum sampled in the experiment was diluted 250 times, 500 times, 1000 times each and reacted at room temperature for 2 hours.
- the anti-Fc-HRP (# 31413, Pierce) antibody was diluted to a concentration of 1: 4000 and reacted at room temperature for 2 hours.
- OPD o-Phenylenediamine dihydrochloride
- the OPD solution was prepared by adding hydrogen peroxide solution and OPD (P9187, Sigma) to PC buffer, pH 5.0. After the reaction in the dark for 10 minutes, 50 ul of 2.5 M sulfuric acid was treated to terminate the color reaction, and absorbance was measured at OD 492 nm.
- the standard curve was processed by selecting a section with an R 2 value of 0.99 or more.
- DLK1-Fc fusion protein has a good potential as a composition for inhibiting the migration of various carcinomas and preventing cancer metastasis in light of pharmacokinetic parameters.
- compositions of the present invention are given below.
- tablets were prepared by tableting according to a conventional method for producing tablets.
- the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
- the DLK1-Fc fusion protein was dissolved in a suitable volume of main sodium chloride BP, and the pH of the resulting solution was adjusted to pH 7.6 with dilute hydrochloric acid BP, and the volume was adjusted with a main volume of sodium chloride BP and mixed well.
- the solution was filled into a 5 ml Type I ampoule made of clear glass, encapsulated under an upper grid of air by dissolving the glass, and sterilized by autoclaving at 120 ° C. for at least 15 minutes to prepare an injection solution.
- DLK1-Fc fusion protein of the present invention has a higher stability than the non-fusion protein, significantly reduces the migration (migration) in a variety of cancer cell lines and is excellent in inhibiting cancer metastasis even at low concentrations, cancer inhibition and cancer prevention and Not only can be usefully used as a therapeutic composition, a composition for preventing or improving health foods, but also when used in combination with an angiogenesis inhibitor composition currently used as a cancer treatment agent, inhibiting cancer metastasis and treating cancer with remarkably excellent anticancer activity It can be usefully used as a composition for.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (14)
- DLK1(delta-like 1 homolog)의 세포외 영역의 수용성 도메인.
- 제 1항에 있어서, DLK1의 세포외 영역의 수용성 도메인은 200 ~ 300 a.a의 크기임을 특징으로 하는 수용성 도메인.
- 제 1항에 있어서, DLK1의 세포외 영역의 수용성 도메인은 서열번호 4로 기재되는 아미노산 서열을 갖는 것을 특징으로 하는 수용성 도메인.
- 제 1항의 DLK1의 세포외 영역의 수용성 도메인 및 인간 항체 Fc 영역이 접합된 DLK1-Fc 융합 단백질.
- 제 4항의 DLK1-Fc 융합 단백질을 코딩하는 폴리뉴클레오티드.
- 제 5항의 폴리뉴클레오티드를 함유하는 재조합 벡터.
- 제 6항의 재조합 벡터가 숙주세포에 형질전환된 재조합 세포주.
- 1) 제 7항의 재조합 세포주를 배양하는 단계; 및2) 세포주 배양액으로부터 DLK1-Fc 융합 단백질을 분리하는 단계를 포함하는 DLK1-FC 융합 단백질 제조방법.
- 제 1항의 DLK1의 세포외 영역의 수용성 도메인 또는 제 3항의 DLK1-Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물.
- 제 9항에 있어서, 상기 암은 피부암, 유방암, 자궁암, 대장암, 신장암, 간암, 폐암, 난소암, 췌장암 및 위암으로 구성된 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 암 전이 억제용 조성물.
- 약학적으로 유효한 양의 제 1항의 DLK1의 세포외 영역의 수용성 도메인 또는 제 3항의 DLK1-Fc 융합 단백질을 전이암에 걸린 개체에 투여하는 단계를 포함하는 암 전이 억제 방법.
- 제 11항에 있어서, 상기 암은 피부암, 유방암, 자궁암, 대장암, 신장암, 간암, 폐암, 난소암, 췌장암 및 위암으로 구성된 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 암 전이 억제 방법.
- 제 1항의 DLK1의 세포외 영역의 수용성 도메인 또는 제 3항의 DLK1-Fc 융합 단백질을 암 전이 억제용 조성물의 제조에 이용하는 용도.
- 제 13항에 있어서, 상기 암은 피부암, 유방암, 자궁암, 대장암, 신장암, 간암, 폐암, 난소암, 췌장암 및 위암으로 구성된 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 용도.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010348423A AU2010348423B2 (en) | 2010-03-16 | 2010-04-13 | Composition for inhibiting cancer metastasis containing DLK1-Fc fusion protein as an active ingredient |
BR112012023416A BR112012023416A2 (pt) | 2010-03-16 | 2010-04-13 | composição para metástase anticâncer contendo proteína de fusão dlk1-fc como um ingrediente eficaz |
EP10838389.4A EP2548887B1 (en) | 2010-03-16 | 2010-04-13 | Composition for inhibiting cancer metastasis containing dlk1-fc fusion protein as an active ingredient |
JP2012505813A JP5367905B2 (ja) | 2010-03-16 | 2010-04-13 | DLK1−Fc融合タンパク質を有効成分として含む癌転移抑制用組成物 |
MX2012010560A MX342222B (es) | 2010-03-16 | 2010-04-13 | Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo. |
US13/142,818 US8785392B2 (en) | 2010-03-16 | 2010-04-13 | Method for inhibiting cancer metastasis by administration of the extracellular domain DLK1 or a DLK1-FC fusion protein |
CN201080013202.XA CN102341408B (zh) | 2010-03-16 | 2010-04-13 | 含有DLK1-Fc融合蛋白作为有效成分的用于抗癌症转移的组合物 |
RU2012143943/10A RU2531756C2 (ru) | 2010-03-16 | 2010-04-13 | СЛИТЫЙ БЕЛОК DLK1-Fc И ЕГО ПРИМЕНЕНИЕ ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗОВ РАКА, ПОЛИНУКЛЕОТИД, КОДИРУЮЩИЙ БЕЛОК, ВЕКТОР, КЛЕТКА-ХОЗЯИН, СПОСОБ ПОЛУЧЕНИЯ СЛИТОГО БЕЛКА, КОМПОЗИЦИЯ И СПОСОБ ИНГИБИРОВАНИЯ МЕТАСТАЗОВ РАКА |
CA2792413A CA2792413C (en) | 2010-03-16 | 2010-04-13 | Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0023180 | 2010-03-16 | ||
KR1020100023180A KR100982170B1 (ko) | 2010-03-16 | 2010-03-16 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011115323A1 true WO2011115323A1 (ko) | 2011-09-22 |
Family
ID=43010111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/002277 WO2011115323A1 (ko) | 2010-03-16 | 2010-04-13 | 디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8785392B2 (ko) |
EP (1) | EP2548887B1 (ko) |
JP (1) | JP5367905B2 (ko) |
KR (1) | KR100982170B1 (ko) |
CN (1) | CN102341408B (ko) |
AU (1) | AU2010348423B2 (ko) |
BR (1) | BR112012023416A2 (ko) |
CA (1) | CA2792413C (ko) |
MX (1) | MX342222B (ko) |
RU (1) | RU2531756C2 (ko) |
WO (1) | WO2011115323A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130080586A (ko) * | 2012-01-05 | 2013-07-15 | 주식회사에이앤알쎄라퓨틱스 | Dlk1 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제 |
WO2015046554A1 (ja) | 2013-09-30 | 2015-04-02 | 中外製薬株式会社 | 改変されたヘルパーファージを用いて抗原結合分子を作製する方法 |
CN104711341A (zh) * | 2013-12-17 | 2015-06-17 | 上海市肿瘤研究所 | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 |
CN108130311A (zh) * | 2017-12-19 | 2018-06-08 | 柴怡 | 一种人原代结肠癌肝转移细胞株hcs1220 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100982170B1 (ko) | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
WO2012138102A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
WO2012138100A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제 |
KR101438265B1 (ko) | 2011-04-04 | 2014-09-05 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
CN102778566B (zh) * | 2011-05-07 | 2016-01-13 | 上海市肿瘤研究所 | Dlk1在肝癌诊断及预后判断中的应用 |
WO2014129590A1 (ja) * | 2013-02-21 | 2014-08-28 | 国立大学法人九州大学 | Cyclin D1遺伝子発現抑制剤および抗腫瘍剤 |
JP7027530B2 (ja) * | 2017-09-08 | 2022-03-01 | ワイ-バイオロジクス インコーポレイテッド | ヒトdlk1に対する抗体及びその用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447851A (en) | 1992-04-02 | 1995-09-05 | Board Of Regents, The University Of Texas System | DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells |
KR20090088893A (ko) * | 2006-11-10 | 2009-08-20 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0673390B1 (en) * | 1992-12-11 | 2000-07-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Delta-like gene expressed in neuroendocrine tumors |
JP2000513329A (ja) * | 1996-03-01 | 2000-10-10 | イムクローン システムズ インコーポレイテッド | 幹細胞の分化を阻害させるためのデルタ様蛋白質の使用 |
US20020064855A1 (en) * | 1999-08-20 | 2002-05-30 | Ihor Lemischka | Genes that regulate hematopoietic blood forming stem cells and uses thereof |
WO2005037867A1 (en) * | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
US8017118B2 (en) | 2008-03-17 | 2011-09-13 | LivTech Inc. — Teikyo University Biotechnology Research Center | Anti-hDlk-1 antibody having an antitumor activity in vivo |
KR100982170B1 (ko) | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
-
2010
- 2010-03-16 KR KR1020100023180A patent/KR100982170B1/ko active IP Right Grant
- 2010-04-13 EP EP10838389.4A patent/EP2548887B1/en not_active Not-in-force
- 2010-04-13 BR BR112012023416A patent/BR112012023416A2/pt not_active Application Discontinuation
- 2010-04-13 CN CN201080013202.XA patent/CN102341408B/zh not_active Expired - Fee Related
- 2010-04-13 JP JP2012505813A patent/JP5367905B2/ja not_active Expired - Fee Related
- 2010-04-13 CA CA2792413A patent/CA2792413C/en not_active Expired - Fee Related
- 2010-04-13 RU RU2012143943/10A patent/RU2531756C2/ru not_active IP Right Cessation
- 2010-04-13 WO PCT/KR2010/002277 patent/WO2011115323A1/ko active Application Filing
- 2010-04-13 AU AU2010348423A patent/AU2010348423B2/en not_active Ceased
- 2010-04-13 MX MX2012010560A patent/MX342222B/es active IP Right Grant
- 2010-04-13 US US13/142,818 patent/US8785392B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447851A (en) | 1992-04-02 | 1995-09-05 | Board Of Regents, The University Of Texas System | DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
KR20090088893A (ko) * | 2006-11-10 | 2009-08-20 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체 |
Non-Patent Citations (28)
Title |
---|
"Remington's Pharmaceutical Science", 1990, MACK PUBLISHING COMPANY |
BAUER SR ET AL., MOLECULAR AND CELLULAR BIOLOGY., vol. 18, 1998, pages 5247 - 55 |
CARLSSON C ET AL., ENDOCRINOLOGY, vol. 138, 1997, pages 3940 - 8 |
CHEN HC, METHODS IN MOLECULAR BIOLOGY, vol. 294, 2005, pages 15 - 22 |
DYCZYNSKA, E. ET AL.: "Proteolytic processing of delta-like 1 by adam proteases.", J. BIOL. CHEM., vol. 282, no. 1, 2007, pages 436 - 444, XP008158124 * |
FLORIDON C ET AL., DIFFERENTIATION, vol. 66, 2000, pages 49 - 59 |
HALDER SK ET AL., ENDOCRINOLOGY, vol. 139, 1998, pages 3316 - 28 |
HUANG J ET AL., CARCINOGENESIS, vol. 28, no. 5, 2007, pages 1094 - 1103 |
JENSEN CH ET AL., EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 225, 1994, pages 83 - 92 |
KANETA M ET AL., JOURNAL OF IMMUNOLOGY, vol. 164, 2000, pages 256 - 64 |
LI L ET AL., ONCOGENE, vol. 24, 2005, pages 4472 - 6 |
LI, L. ET AL.: "Expression of DLKl in hematopoietic cells results ininhibition of differentiation and proliferation.", ONCOGENE, vol. 24, 2005, pages 4472 - 4476, XP008158126 * |
MEG L ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 378, 2007, pages 33 - 52 |
SAKAJIRI S ET AL., LEUKEMIA, vol. 19, 2005, pages 1404 - 10 |
SAMULEWICZ SJ ET AL., WOUND REPAIR AND REGENERATION., vol. 10, 2002, pages 215 - 21 |
SCHMIDT JV ET AL., GENES AND DEVELOPMENT., vol. 14, 2000, pages 1997 - 2002 |
See also references of EP2548887A4 |
SMAS CM ET AL., BIOCHEMISTRY, vol. 33, 1994, pages 9257 - 65 |
SMAS CM ET AL., CELL, vol. 73, 1993, pages 725 - 34 |
SMAS CM ET AL., CELL, vol. 73, pages 725 - 34 |
SMAS CM, SUL HS, CELL, vol. 73, 1993, pages 725 - 34 |
TAKADA S ET AL., CURRENT BIOLOGY, vol. 10, 2000, pages 1135 - 8 |
VILLENA JA ET AL., HORMONE AND METABOLIC RESEARCH, vol. 34, 2002, pages 664 - 70 |
WYLIC AA ET AL., GENOME RESEARCH., vol. 10, 2000, pages 1711 - 8 |
YIN D ET AL., ONCOGENE, vol. 25, 2006, pages 1852 - 61 |
YUHUI WANG ET AL., JOURNAL OF NUTRITION, vol. 136, 2006, pages 2953 - 2956 |
YUHUI WANG, HEI SOOK SUL, MOLECULAR AND CELLULARBIOLOGY, vol. 26, no. 14, 2006, pages 5421 - 5435 |
YURI K ET AL., CANCER RESEARCH, vol. 69, no. 24, 2009, pages OF1 - 10 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130080586A (ko) * | 2012-01-05 | 2013-07-15 | 주식회사에이앤알쎄라퓨틱스 | Dlk1 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제 |
US20150030595A1 (en) * | 2012-01-05 | 2015-01-29 | Antibody And Receptor Therapeutics Co., Ltd. | Myostatin Inhibitor Comprising Extracellular Water-Soluble Domains of DLK1 As Active Ingredient |
US9388223B2 (en) * | 2012-01-05 | 2016-07-12 | Antibody And Receptor Therapeutics Co., Ltd. | Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient |
KR101995751B1 (ko) * | 2012-01-05 | 2019-07-03 | 주식회사 와이바이오로직스 | Dlk1 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제 |
WO2015046554A1 (ja) | 2013-09-30 | 2015-04-02 | 中外製薬株式会社 | 改変されたヘルパーファージを用いて抗原結合分子を作製する方法 |
EP3940065A1 (en) | 2013-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Method for producing antigen-binding molecule using modified helper phage |
CN104711341A (zh) * | 2013-12-17 | 2015-06-17 | 上海市肿瘤研究所 | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 |
CN104711341B (zh) * | 2013-12-17 | 2019-10-22 | 上海市肿瘤研究所 | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 |
CN108130311A (zh) * | 2017-12-19 | 2018-06-08 | 柴怡 | 一种人原代结肠癌肝转移细胞株hcs1220 |
Also Published As
Publication number | Publication date |
---|---|
US20130202592A1 (en) | 2013-08-08 |
CN102341408A (zh) | 2012-02-01 |
CA2792413C (en) | 2015-12-01 |
MX2012010560A (es) | 2012-12-10 |
JP2012513775A (ja) | 2012-06-21 |
US8785392B2 (en) | 2014-07-22 |
EP2548887A1 (en) | 2013-01-23 |
KR100982170B1 (ko) | 2010-09-15 |
JP5367905B2 (ja) | 2013-12-11 |
CN102341408B (zh) | 2014-09-10 |
MX342222B (es) | 2016-09-21 |
RU2012143943A (ru) | 2014-04-27 |
RU2531756C2 (ru) | 2014-10-27 |
EP2548887A4 (en) | 2013-12-04 |
EP2548887B1 (en) | 2015-05-27 |
CA2792413A1 (en) | 2011-09-22 |
BR112012023416A2 (pt) | 2017-03-21 |
AU2010348423B2 (en) | 2014-04-10 |
AU2010348423A1 (en) | 2012-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011115323A1 (ko) | 디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 | |
JP2997053B2 (ja) | ヒトリンパ球により生成されるタンパク質、それらのタンパク質をコードするdna配列及びそれらの医薬及び生物学的使用 | |
US4190646A (en) | Polypeptide compositions and methods | |
WO2013169060A1 (ko) | 패혈증 예방 또는 치료용 조성물 | |
SE504554C2 (sv) | Ett nytt bifunktionellt tillväxtmodulerande glykoprotein | |
WO2016190660A1 (ko) | 신규 펩티드 및 이를 포함한 조성물 | |
EP0074787B1 (en) | Renally active dipeptides | |
WO2018074682A1 (ko) | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 | |
CS251085B2 (en) | Method of peptides production liberating growth hormone | |
EP0094233B1 (en) | Immune modulator peptides | |
JPH07502171A (ja) | 新規ポリペプチドおよびペプチド、それらをコードする核酸、ならびに、腫瘍治療、炎症あるいは免疫学の分野におけるそれらの使用 | |
WO2022108306A1 (ko) | 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 | |
US6645498B1 (en) | Soluble variants of type I membrane proteins, and methods of using them | |
CA1105923A (en) | Pentapeptides and methods | |
US4258152A (en) | Pentapeptide modified resin | |
WO2023249439A1 (ko) | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 | |
WO2024122718A1 (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
GB1590457A (en) | Thymosin a1 | |
WO2022019652A1 (ko) | IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도 | |
WO2024122717A1 (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
US4478828A (en) | Nonapeptide having immunostimulative activity, process for the preparation thereof, and its use | |
WO2023182657A1 (ko) | 항-fetuin-b 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물 | |
WO2021225399A1 (ko) | 암 치료를 위한 키메라 항원 수용체 | |
AU678917B2 (en) | Peptides with organo-protective activity, their preparation and use | |
SK279227B6 (sk) | Peptidy s ochrannou aktivitou na organizmus, terap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080013202.X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012505813 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010838389 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10838389 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13142818 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2792413 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/010560 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2198/MUMNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012143943 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2010348423 Country of ref document: AU Date of ref document: 20100413 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012023416 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012023416 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120917 |